Akebia Therapeutics, Inc.

The Procter Gamble Company

Warner Chilcott Company, LLC

Namal Chithranga Warshakoon

Artem G Evdokimov

Richard Masaru Kawamoto

Kenneth D Greis

Angelique Sun Boyer

Shengde Wu

Rodney D Bush

Artem G Edokimov

Kenneth Donald Greis

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Prolyl hydroxylase inhibitors and methods of use

The present disclosure relates to HIF-1&#x3b1; prolyl hydroxylase inhibitors, compositions which comprise the HIF-1&#x3b1; prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Prolyl hydroxylase inhibitors and method of use

Compounds of Formula (I) are effective in the treatment of a microbial infection.

N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones

Compounds of Formula (I): are effective in the treatment of a microbial infection.

N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones

Compounds of Formula (I)are effective in the treatment of a microbial infection.

Growing community of inventors

Mason, OH, United States of America

Namal Chithranga Warshakoon